Aclaris Therapeutics is a clinical-stage company that identifies, develops, and seeks to commercialize innovative therapies to address significant unmet needs in medical and aesthetic dermatology. The company is focused on underserved market segments with no FDA- approved medications or where treatment gaps exist. ACRS’ lead clinical asset, A-101 40% topical solution, is a high-concentration hydrogen peroxide formulation for the treatment of seborrheic keratosis (SK). A 45% topical solution of A-101 is also in clinical development for verruca vulgaris (common warts). Additionally, ACRS expanded its pipeline beyond A-101 with the acquisition of a portfolio of Janus Kinase (JAK) inhibitor compounds. The company is developing several treatments for alopecia areata (autoimmune skin disease characterized by hair loss on the scalp and body), androgenetic alopecia (male/female pattern hair loss) and vitiligo (autoimmune disease in which the skin loses its pigment).

Seborrheic keratosis is a skin condition that affects more than 83 million Americans. It is one of the most frequent diagnoses made by dermatologists, yet fewer than 10% of people with SK receive treatment. Currently, there are no FDA-approved medications for SK. Current treatments are painful and often leave depigmentation.

ACRS is also developing JAK inhibitors, ATI-50001 and ATI-50002, for the treatment of alopecia areata (AA), androgenetic alopecia, and vitiligo. Each of these indications represent large market opportunities and Foresite Capital believes ATI-50001 and ATI-50002 could drive significant value.